|
|
||||||||
1 Department of Biochemistry and Molecular Biology, and 2 Department of Physiology, University of Maryland School of Medicine, and 3 Medical Biotechnology Center, University of Maryland Biotechnology Institute, University of Maryland School of Medicine, Baltimore, Maryland 21201
| |
ABSTRACT |
|---|
|
|
|---|
Calyculin A was used to examine the
importance of phosphatases in the modulation of cardiac contractile
magnitude in the absence of any neural or humoral stimulation. Protein
phosphatase (PP)1 and PP2A activity, twitch contractions, intracellular
Ca2+ concentration ([Ca2+]i)
transients, action potentials, membrane currents, and myofilament Ca2+ sensitivity were measured in isolated mouse
ventricular myocytes. Calyculin A (125 nM) inhibited PP1 and PP2A by
50% and 85%, respectively, whereas it doubled the twitch magnitude
and increased twitch duration by 50% in field-stimulated cells.
Calyculin A-evoked increases in L-type Ca2+ current (70%)
and the resulting [Ca2+]i transient (83%)
explain the positive inotropic response. However, increases in twitch
and action potential durations did not result from increased
myofilament Ca2+ sensitivity or K+ current
inhibition, respectively. Comparison of the effects of calyculin A and
isoproterenol on [Ca2+]i transients and
twitch contractions revealed that calyculin A had a much smaller
lusitropic effect than the
-agonist, indicating that calyculin A did
not significantly increase sarcoplasmic reticulum Ca2+
reuptake. Thus while cardiac contractile magnitude is controlled by a
steady-state kinase/phosphatase balance, this regulation is not equally
operative at all of the steps in the excitation-contraction coupling
pathway and may in fact be most important to the regulation of the
L-type Ca2+ channel.
calcium current; calcium transient; phosphorylation; indo 1; fluo 3
| |
INTRODUCTION |
|---|
|
|
|---|
INTRACELLULAR SIGNALING
SPECIFICITY is determined in part by targeting of signaling
cascades to discrete subcellular locations. In heart cells, A-kinase
anchoring proteins are important in defining the signaling specificity
of protein kinase A (PKA) (11) and may be essential for
L-type Ca2+ channel regulation (22). There is
also evidence for protein kinase C (PKC)-
targeting in heart cells
(37, 45). Yet much less is known of the phosphatases that
oppose the action of such kinases. Biochemical studies (34,
47) suggest that protein phosphatase (PP)1 acts as a
phospholamban phosphatase regulating sarcoplasmic reticulum (SR)
function, whereas PP2A may regulate myofilament function as a
"troponin I phosphatase" (38). Furthermore, immunoprecipitation studies (10, 35, 36) have shown that PP2A is directly associated with the cardiac ryanodine receptor and the
1-subunit of the L-type Ca2+ channel. The
fact that these enzymes can be precisely targeted suggests they are
important signaling elements. However, the physiological roles of these
signaling enzymes in cardiac cells remain to be defined.
Phosphatase inhibitors can reveal the presence of a dynamic balance between protein phosphorylation and dephosphorylation. PP1/PP2A inhibitors, such as okadaic acid and calyculin A, have been shown to stimulate L-type Ca2+ channel function in the absence of humoral stimulation (27, 28, 40, 41). Addition of exogenous phosphatases can also reveal such a dynamic balance. A previous study (13) from this laboratory demonstrated that intracellular dialysis of rat ventricular myocytes with either PP1 or PP2A decreased the magnitude of the cytosolic intracellular Ca2+ concentration ([Ca2+]i) transient in the steady state without decreasing SR Ca2+ load. These studies reveal the importance of phosphatases in local control in the heart. In fact, because PP1/PP2A comprise the majority of serine-threonine phosphatase activity within cells, it might be expected that these enzymes are important regulators of many components of the excitation-contraction (E-C) coupling cascade, including the membrane currents involved in excitation, the proteins involved in uptake and release of Ca2+, and the myofilaments that transduce the Ca2+ signal into mechanical activity.
In the present study, calyculin A, a potent inhibitor of PP1 and PP2A (30), was used to characterize which components of the E-C coupling cascade are regulated by such a kinase/phosphatase balance in mouse ventricular myocytes. The murine heart model was chosen so that the results could be used to design future studies to exploit transgenic animal models. The goals of this study were as follows: 1) to accurately and precisely measure the activity of PP1 and PP2A and their inhibition by calyculin A in mouse ventricular myocytes, 2) to define the biological role of calyculin A-sensitive PP1 and PP2A in maintaining cardiac contractility in the absence of any receptor-activated signaling, and 3) to identify the specific components of the cardiac E-C coupling cascade whose activities are controlled in this manner. An important conclusion from these studies is that PP1 and/or PP2A, in concert with as-yet-unidentified protein kinase(s), control the level from which receptor-activated signaling pathways regulate contractility. This function is carried out primarily through control of L-type Ca2+ current (ICa) rather than by acting at all of the steps of the E-C coupling cascade.
| |
METHODS |
|---|
|
|
|---|
Cardiac myocyte preparation. Hearts were removed from adult male CD-1 mice anesthetized with 30 mg/kg ip of pentobarbital sodium (Abbott Laboratories). The aorta was cannulated for Langendorff perfusion, and ventricular myocytes were isolated by a standard enzymatic technique exactly as described previously (14). The cells were maintained at room temperature in HEPES-buffered DMEM with 10% fetal calf serum. All experiments were carried out within 8 h of cell isolation.
Incubation with calyculin A. Cells were preincubated with varying concentrations (100 nM-1 µM) of calyculin A (Alexis Biochemicals) from a 1 mM stock in DMSO. Control cells were preincubated with equal volumes of DMSO alone. Calyculin A was present only during the preincubation period. After 15-30 min of preincubation, the cells were used for either biochemical or functional experiments. A small number of experiments (summarized in Fig. 7) were performed in which cells were exposed to calyculin A and staurosporine during voltage-clamp experiments. Voltage-clamp recordings were made in control, in the presence of calyculin A (100 nM), or with the serine-threonine protein kinase inhibitor staurosporine (300 nM) and then in the presence of both calyculin A and staurosporine. Both agents were added from stock solutions in DMSO, and an equal concentration of DMSO (0.04%) was present in all of the experimental solutions.
Phosphatase assays.
Suspensions of myocytes were rapidly washed with 0.9% NaCl and then
homogenized in lysis buffer consisting of HEPES-NaOH (20 mM, pH 7.5),
NaCl (100 mM), protease inhibitor cocktail (1:400, Sigma P8340), and
0.02%
-mercaptoethanol. The cell extracts were centrifuged at
178,000 g for 10 min at 4°C. Protein concentration in the
supernatant was determined spectrophotometrically with Bradford's
reagent (Bio-Rad) using BSA as the standard.
-mercaptoethanol, 3.3 mM caffeine, 0.25 mg/ml
[32P]phosphorylase a, and 350 ng supernatant
protein. After a 15-min incubation period at 30°C, the reaction was
stopped by adding 180 µl of 20% (vol/vol) trichloroacetic acid
(TCA). After an additional 10 min on ice, the mixture was centrifuged
at 12,000 g for 3 min at 4°C. The supernatant was
collected, and the amount of 32Pi released
during the reaction was quantified by liquid scintillation counting.
PP1 specific activity, expressed as nanomoles of
32Pi released per minute per milligram of
protein, was defined as the activity measured in the presence of 10 nM
okadaic acid minus the residual activity in the presence of 500 nM
okadaic acid. The specificity of the assay is depicted in Fig.
1A.
|
-32P]ATP with 40 µg unphosphorylated peptide in a
200-µl total volume containing 10 units of the PKA catalytic subunit
(Sigma), 70 mM MES, and 15 mM MgCl2. After 1 h of
incubation at 30°C, 10 more units of PKA were added, and the reaction
was continued for another hour. The reaction was stopped by adding 200 µl of 30% acetic acid. The 32P-labeled phosphopeptide
was purified by applying the reaction volume onto a preequilibrated
solid-phase extraction column (Sep-Pak C18 cartridges, Waters). The
column was then washed with 0.1% trifluoroacetic acid (TFA) until the
radioactivity of the effluent was <1,000
counts · min
1 · µl
1. The
phosphopeptide was eluted as one radioactive peak with successive additions of 500 µl of 30% acetonitrile in 0.1% TFA. The effluents containing the highest concentration of 32P-labeled RRATpVA
were combined, aliquoted, and frozen for use.
To assay PP2A activity, cell extracts (0.4 µg of protein) were
incubated with 20,000 counts/min of 32P-labeled RRATpVA in
reaction buffer containing 20 mM HEPES-NaOH (pH 7.5), 100 mM NaCl, and
0.02%
-mercaptoethanol in the presence or absence of 10 nM okadaic
acid. After 15 min of incubation at 30°C, the reaction was terminated
by adding 500 µl of 100 mM K2PO4 in 5% TCA.
The 32P-labeled peptide and 32Pi
released were separated by applying the total reaction volume (550 µl) onto an ion exchange column (1 ml Dowex 50WX8 200-400 mesh,
H form). The 32Pi was eluted from the columns
in 500 µl H2O and quantified by liquid scintillation
counting. It is important to note that the assay was linear with
respect to both protein and time under these conditions. PP2A activity,
expressed as femtomoles of 32Pi released per
minute per milligram of protein, was defined as the component of total
phosphatase activity that was inhibited by 10 nM okadaic acid (Fig.
1B). The specificity of the assay for PP2A is clearly
demonstrated in Fig. 1B. With the use of RRATpVA, ~85% of
the total activity was sensitive to 10 nM okadaic acid, a concentration
that is without effect on PP1. Thus the use of these two assays in
parallel allows the precise measurement of PP1 and PP2A activity in
crude cardiac cell extracts.
Field stimulation and edge detection. These experiments were conducted at room temperature on a Nikon Diaphot inverted microscope. Cells were superfused with extracellular buffer consisting of 100 mM NaCl, 5 mM KCl, 25 mM NaHCO3, 25 mM HEPES, 1.0 mM Na2HPO4, 1.0 mM MgSO4, 10 mM D-glucose, and 1.8 mM CaCl2 at pH 7.4 (NaOH). Cells were field stimulated (Grass S48) at 1 Hz with 5-ms pulses with a magnitude of ×1.5 threshold through platinum wires mounted in the bottom of the experimental chamber. Twitch contractions were recorded using a video-based edge detector (Crescent Electronics), digitized at 500 Hz (PP-50 Lab Patch Panel, Warner Instrument and Axotape, Axon Instruments), and analyzed off-line. Contractions were normalized to the resting cell length.
Field stimulation and [Ca2+]i transients. Cells were loaded with fluo 3 by incubating a 2-ml cell suspension with 30 µl of 0.5 µg/µl fluo 3-AM stock in 20% (wt/vol) pluronic F-127 in DMSO. The final concentration of fluo 3-AM was 6.6 µM. Fluo 3-loaded cells were field stimulated (1 Hz) as described in Field stimulation and edge detection on a Bio-Rad MRC 600 laser scanning confocal microscope equipped with a Zeiss Neofluor ×63 oil immersion lens (numerical aperture = 1.25). Images were obtained in line-scan mode, processed, and analyzed using COMOS (Bio-Rad) and IDL5.2 (Research Systems) software. To measure [Ca2+]i transients, the fluorescence images were normalized by dividing the fluorescence intensity of each pixel (F) by the average resting fluorescence intensity (F0) to generate an F/F0 image. Cell length during each line scan was measured by determining the portion of the scan line that exhibited fluo 3 fluorescence.
Action potential measurements. Action potential measurements were made at 35°C using low-resistance patch type microelectrodes and an Axopatch 200A with a CV202A head stage (Axon Instruments). The filling solution consisted of the following: 110 mM potassium aspartate, 20 mM KCl, 10 mM NaCl, 4 mM MgATP, and 10 mM HEPES at pH 7.3 (with KOH). The extracellular solution was the same as that used for the field stimulation experiments. The cells were stimulated (1 Hz) by applying a brief (2-5 ms) hyperpolarizing current clamp pulse. After release of this pulse, the cells reached threshold and generated an action potential.
Voltage-clamp experiments.
These experiments were conducted at 35°C on a Nikon Diaphot 200 inverted microscope that was modified, as previously described (13), for the simultaneous measurement of membrane current
and [Ca2+]i. The voltage-clamp amplifier was
an Axopatch 200A with a CV202A head stage. Whole cell voltage clamp was
carried out using low-resistance (<2 M
) patch type microelectrodes.
Cells were placed in the experimental chamber and superfused with a
solution containing 140 mM NaCl, 5 mM KCl, 10 mM HEPES, 1 mM
MgCl2, 0.33 mM NaH2PO4, and 10 mM D-glucose at pH 7.4 (with NaOH). The pipette filling
solution used for simultaneous measurements of
ICa and the cytosolic Ca2+
([Ca2+]i) transient consisted of 130 mM CsCl,
10 mM HEPES, 20 mM TEA chloride, 1.0 mM MgCl2, 5.0 mM
MgATP, and 25 µM K5indo 1 at pH 7.3 (with CsOH). After
whole cell access was attained, a modified superfusate was used, which
included CsCl (substituted for KCl), 5 mM 4- aminopyridine, 10 mM TEA
chloride to block K+ channels, and 10 µM TTX to block
Na+ channels. Extracellular Ca2+
concentration ([Ca2+]o) was 1.8 mM
(CaCl2). ICa was recorded from a
holding potential of
40 mV. [Ca2+]i was
calibrated using a previously described in vitro technique (13). K+ currents were recorded using
KCl-based intra- and extracellular solutions as described previously
(14). [Ca2+]o was 0.1 mM, and
nifedipine (0.5 µM) and TTX (10 µM) were included to block
ICa and Na+ current, respectively.
70 to
80 mV.
Myofilament Ca2+ sensitivity. These experiments were conducted on the same apparatus used to measure field-stimulated twitch contractions. EGTA-buffered solutions consisting of (in mM) 7 EGTA, 25 imidazole, 1 MgCl2, 80 KCl, and 4 MgATP at pH 7.0 (with KOH) (29) were prepared at the following Ca2+ concentrations (in nM): 1, 100, 200, 300, 400, and 500. The amount of CaCl2 required to achieve each Ca2+ concentration was calculated using a computer program that can account for the binding of Ca2+ and other cations to EGTA and the other constituents of the solution (16). CaCl2 was added from a 250 mM stock prepared using a calcium standard solution (EM Science). An aliquot of cells was placed in the experimental chamber and superfused with solution containing 1 nM Ca2+. After several minutes of superfusion, cells were exposed for 1 min to a solution containing 1 nM Ca2+ and 10 µM digitonin (Sigma). Preliminary experiments showed that this was sufficient to permeabilize the myocytes. This was followed in succession by 5 min of superfusion with digitonin-free solutions described above (1-500 nM Ca2+). During the last minute of exposure in each concentration, when cell length had reached a new steady state, a measurement was taken. Myofilament Ca2+ sensitivity was assessed by normalizing cell length at each Ca2+ concentration to that at 1 nM Ca2+ and plotting the resulting average shortening values versus Ca2+ concentration.
Statistics. The experimental values are expressed as means ± SE, with statistical significance (P < 0.05) assessed using Student's paired t-test.
| |
RESULTS |
|---|
|
|
|---|
A recent report (13) from this laboratory
demonstrated that increasing the activity of PP1 or PP2A in cardiac
cells had selective effects on elements of the E-C coupling cascade. In the present study, we used PP1 and PP2A inhibitors to further explore
the selectivity and targeting of phosphatase action. Although there are
several PP1/PP2A inhibitors that are frequently used in biochemical
studies, it is essential to confirm their efficacy and specificity in
intact cells (17). Accordingly, experiments were designed
to assess the ability of phosphatase inhibitors to act on these enzymes
in intact murine ventricular myocytes, as described in Fig. 1 and
METHODS. Initial experiments with okadaic acid revealed
that even long incubations (2 h) resulted in only minimal inhibition of
PP1 or PP2A (data not shown). This is likely due to its low membrane
permeability (17). The effects of calyculin A were quite
different, as shown in Fig. 2. A 15-min
incubation with 125 nM calyculin A resulted in inhibition of PP1
activity by 52%, whereas 1 µM calyculin A further reduced the
activity to 34% of control. Calyculin A proved to be a more potent
inhibitor of PP2A under these conditions, reducing the activity to zero at a concentration of 1 µM. Accordingly, calyculin A was used in all
of the studies described below.
|
On the basis of these results, we examined the effects of calyculin A
on the twitch contractions of single isolated mouse ventricular
myocytes. In fact, calyculin A had a profound effect on the
field-stimulated twitch contraction, as shown in Fig.
3. Calyculin A (125 nM) increased the
average magnitude of contraction by 106%, from 8.6 ± 0.6%
(n = 26) to 17.7 ± 0.7% (n = 17)
of resting length. The duration of the contraction, measured as the
time from 50% contraction to 50% relaxation, was also greater,
increasing by 47% from 109 ± 3 to 159 ± 7 ms. These
effects were maximal, because there was no additional effect of 1 µM
calyculin A (n = 18) on twitch magnitude (17.5 ± 0.9% of resting length) or duration (156 ± 4 ms). Interestingly,
although the twitch was greatly prolonged in calyculin A, there was no
effect on the kinetics of twitch relaxation. The average time constant
(
) of relaxation was 39 ± 1 ms in control and 43 ± 3 ms
in cells preincubated with calyculin A. The lack of effect of calyculin
A on relaxation kinetics is apparent in the normalized contractions
shown in Fig. 3B.
|
Increased myofilament Ca2+ sensitivity could explain the
effects of calyculin A on the twitch contraction. Thus chemically
skinned isolated mouse ventricular myocytes were used to measure
possible increases in myofilament Ca2+ sensitivity. After
preincubation in DMSO alone or in calyculin A, cells were permeabilized
on the microscope stage with 10 µM digitonin. Cell length was
measured after equilibration with solutions containing free
Ca2+ concentrations ranging from 1 to 500 nM. The results
are summarized in Fig. 4. Control cells
exhibited no change in length as the Ca2+ concentration in
the superfusate was increased from 1 to 100 nM. However, there was a
significant decrease in length, to 99.2 ± 0.3% of resting length
(P = 0.009), as the Ca2+ concentration was
increased from 100 to 200 nM. There were additional incremental
decreases in cell length (P < 0.05) as
[Ca2+]o was increased to a concentration of
500 nM. The mean cell length at 500 nM Ca2+ was 91.9 ± 1.1% of resting length. Above 500 nM Ca2+, most cells
hypercontracted, presumably because of the absence of a mechanical
load. To validate that increases in myofilament Ca2+
sensitivity could be detected, the Ca2+ dependence of cell
length was measured in the presence of caffeine (15, 49).
As expected, caffeine significantly increased the extent of shortening
at 200 nM Ca2+ (P = 0.012), and the effect
persisted as [Ca2+]o was increased
(P < 0.05). The effects of the PKA activator 8-bromo-cAMP were also examined (25, 42). Cells
preincubated with 20 µM 8-bromo-cAMP exhibited less shortening than
control cells at all concentrations of Ca2+. The effect
reached statistical significance at 500 nM Ca2+, with
shortening to 95.8 ± 0.9% of resting length compared with 91.9 ± 1.1% in control (P = 0.03). Importantly,
calyculin A-treated cells did not exhibit an increase in myofilament
Ca2+ sensitivity. In fact, there was no statistical
difference, at any [Ca2+] tested, between the extent of
shortening in the control cells and those preincubated with
calyculin A. Although this technique is limited in its ability to
measure myofilament Ca2+ sensitivity over the complete
range of physiologically relevant Ca2+ concentrations, it
is very effective in measuring Ca2+ sensitivity in the
100-500 nM range, where increases in Ca2+ sensitivity
are very evident. Thus the results of these experiments reveal that the
increase in contraction produced by calyculin A is not due to an
increase in steady-state myofilament Ca2+ sensitivity.
|
It is possible that phosphatase inhibition could lead to targeted
changes in one or more of the ionic currents that underlie the mouse
ventricular action potential and thus produce the characteristic effects of calyculin A on the twitch. We began our analysis of this
hypothesis by examining the effects of calyculin A on the action
potential (Fig. 5A). Calyculin
A prolonged the duration of the action potential, increasing the time
to 50% repolarization from 3.6 ± 0.7 ms (n = 5)
to 8.6 ± 1.0 ms (n = 5, P = 0.001) without having any effect on the resting potential (control:
73.5 ± 0.9 mV; calyculin A:
70.6 ± 1.6 mV,
P = 0.19). These results suggest that
electrophysiological actions of calyculin A are responsible for its
characteristic effects on twitch magnitude and duration.
|
Calyculin A could increase the action potential duration by decreasing
the activity of PP1 or PP2A involved in controlling the amplitude of
repolarizing K+ currents. This was tested with whole cell
voltage-clamp experiments on the inward rectifier K+
current (IK1), which is primarily responsible
for determining the resting potential, and on the time- and
voltage-dependent currents that underlie action potential
repolarization. The effect of calyculin A on IK1
was examined by applying 300-ms test pulses to potentials between
120
and
40 mV from a holding potential of
70 mV. The magnitude of
IK1 was calculated as the difference between the
current at the end of the pulse and the holding current. The results
are summarized in Fig. 5B, with average current-voltage relationships recorded from control cells (n = 6) and
cells preincubated with calyculin A (n = 5). Figure
5B demonstrates that calyculin A is without effect on
IK1.
Figure 5, C-E, summarizes the effects of calyculin A on the voltage- and time-dependent K+ currents that are responsible for action potential repolarization. In both control cells and in cells preincubated with calyculin A, the composite K+ currents exhibit a large and rapid outward transient, followed by decay to a maintained outward current (Fig. 5C). This is consistent with a recent study (14) from this laboratory and others (19, 51, 53), demonstrating that the composite mouse ventricular K+ current consists of contributions from at least three time- and voltage-dependent K+ currents, each with distinct activation and inactivation kinetics. Importantly, the average results presented in Fig. 5D indicate that calyculin A had no effect on the voltage dependence of either the transient or maintained components of the composite current. Because the contractile effects of calyculin A were manifest at a stimulation rate of 1 Hz (Fig. 3), it was also necessary to examine the recovery from inactivation of these currents. Recovery from inactivation was examined between 20 and 2,800 ms. Figure 5E shows that the time course of recovery of both the transient and sustained components of the current was unaffected by calyculin A. Thus the K+ currents that are important components of the mouse ventricular action potential are insensitive to calyculin A, revealing that localized phosphatase activity is not responsible for maintaining the steady-state amplitude of these currents.
Increased ICa could explain the effect of
calyculin A on the action potential as well as directly account for the
increased contraction magnitude. This possibility was examined under
conditions in which ICa and cytosolic
[Ca2+]i transients were recorded
simultaneously. The Ca2+-sensitive fluorescent indicator
indo 1 was included in the pipette filling solution, and
[Ca2+]i was quantified using an in vitro
calibration method (13). Figure
6A shows representative
original records, and Fig. 6B shows the average voltage
dependence of both ICa and the
[Ca2+]i transient recorded from control cells
and cells preincubated with calyculin A. The phosphatase inhibitor
increased both ICa and the
[Ca2+]i transient (P < 0.05)
throughout the entire range of test potentials. For example,
ICa is increased at 0 mV from 7.9 ± 0.6 pA/pF in control to 13.8 ± 0.8 pA/pF with calyculin A. Whereas
the magnitude of ICa was markedly increased, the
kinetics of ICa decay, examined between
14 and
+28 mV, were unaffected by calyculin A. Currents recorded in both
control and calyculin A exhibited biexponential decay, with a fast
of <10 ms and a slower component with a
between 30 and 50 ms. For
example, the average fast
at 0 mV was 6.0 ± 0.4 ms
(n = 6) in control and 6.5 ± 0.5 ms
(n = 5) with calyculin A (P = 0.21).
The respective slow
were 39.4 ± 3.4 and 37.0 ± 2.0 ms
(P = 0.29).
|
Like ICa, the [Ca2+]i
transient was also markedly increased by calyculin A (Fig. 6). For
example, the average peak [Ca2+]i at 0 mV was
827 ± 90 nM in control cells and 1,514 ± 185 nM in treated
cells. Interestingly, however, the [Ca2+]i
transients recorded from voltage-clamped cells preincubated with
calyculin A exhibited accelerated decay with respect to control. The
average
of decay of [Ca2+]i transients
elicited during steady-state drives to 0 mV was 188 ± 17 ms
(n = 4) in control cells and 128 ± 17 ms
(n = 4) in cells preincubated in calyculin A
(P = 0.02). These results demonstrate that calyculin A
elicits a marked increase in ICa, which in turn produces an increase in the [Ca2+]i transient
that activates contraction.
In a dynamic phosphorylation model, the functional effects of
phosphatase inhibition are seen through the activity of a counteracting kinase. Thus phosphatase inhibition should be without effect once the
kinase activity has been inhibited. Accordingly, the specificity of
calyculin A was examined in combination experiments with the broad-spectrum serine-threonine kinase inhibitor staurosporine (46). As shown in Fig.
7B, staurosporine decreased
steady-state ICa and, importantly, completely
blocked the stimulatory action of calyculin A (Fig. 7B). The
results of the reverse experiment were also consistent with this model,
because staurosporine was completely without effect once the responses
to calyculin A were fully developed (Fig. 7C). Thus the
effects of calyculin A on ICa occur through
phosphatase inhibition rather than through a nonspecific effect of this
agent on Ca2+ channels.
|
These data demonstrate that the increase in the twitch contraction seen in Fig. 3 can be explained by an increase in ICa brought about specifically by the phosphatase inhibition produced by calyculin A. However, recall the effects of calyculin A described above on the kinetics of [Ca2+]i transient decay (Fig. 6) and twitch contraction (Fig. 3). When these are compared, there is an apparent discrepancy, with calyculin A accelerating the decay of the voltage-clamp-induced [Ca2+]i transient while it prolongs the duration of the field-stimulated twitch contraction.
To address this discrepancy, we measured
[Ca2+]i transients and twitch contractions
simultaneously in field-stimulated cells. This allowed us to examine
the relationships among the magnitudes, durations, and kinetics of the
[Ca2+]i transients and resulting twitch
contractions. The measurements were made in fluo 3-AM-loaded cells
using a laser scanning confocal microscope in the line-scan mode. A
representative line-scan image and [Ca2+]i
transient (F/F0) are shown in Fig.
8, and the results are summarized in
Table 1. As in cells not loaded with
fluorescent dye (Fig. 3), calyculin A markedly increased the magnitude
and duration of the field-stimulated twitch contraction. Also, as
expected from Fig. 6, calyculin A markedly increased the magnitude of
the field-stimulated [Ca2+]i transient.
However, despite the fact that the
of decay of the
[Ca2+]i transient was accelerated by 25%,
the duration of the [Ca2+]i transient,
measured as the time to 50% decay (T50), was
not significantly different from control. This suggests that calyculin A does not substantially stimulate SR Ca2+ uptake.
|
|
To test the role of PP1/PP2A in regulating SR Ca2+ uptake,
we compared the effects of calyculin A (125 nM) with those of the
-adrenergic agonist isoproterenol (1 µM).
-Adrenergic
stimulation is known to greatly stimulate the activity of the SR
Ca2+ pump. The magnitudes of both the
[Ca2+]i transient and contraction were the
same in isoproterenol as in calyculin A (Table 1). However, the effects
of isoproterenol on the kinetics of the
[Ca2+]i transient were quite distinct from
those of calyculin A. Whereas calyculin A was without effect on the
T50 of the [Ca2+]i
transient, isoproterenol decreased this parameter by ~25%. Furthermore, isoproterenol decreased the
of
[Ca2+]i decay by ~50%, essentially
doubling the effect of calyculin A. Calyculin A and isoproterenol had
identical effects on the action potential and
ICa, and, importantly, isoproterenol was without
effect on ICa after calyculin A (data not
shown). Thus the differences between the effects of calyculin A and
isoproterenol on the [Ca2+]i transient
kinetics cannot be attributed to different effects on these factors.
Taken together, these data suggest that any effects of PP1 or PP2A
inhibition on the rate of SR Ca2+ uptake are minimal
compared with the increase produced by
-adrenergic stimulation.
However, inhibition of one or both of these phosphatases results in a
marked increase in ICa, which translates into a
substantial increase in the magnitude and duration of contraction.
| |
DISCUSSION |
|---|
|
|
|---|
Phosphatase inhibition has been shown to have a wide variety of
effects on cardiac cells. It can modify the responses to adenosine receptor stimulation (39), classic
-adrenergic
stimulation (26, 27), and
2-adrenergic
stimulation (32). On its own, phosphatase inhibition has
also been shown to mimic the cardioprotective effects of
ischemic preconditioning (2, 3). With respect to
the E-C coupling cascade, Ca2+ currents increase during
phosphatase inhibition (20, 40, 41, 43, 50), and
biochemical measurements have also indicated that myofilament proteins
and phospholamban can become phosphorylated (4, 40, 41).
Thus because most of the components of the E-C coupling cascade are
known to be regulated in some fashion by phosphorylation, it was
expected that nearly complete inhibition of the major serine-threonine
phosphatase activity in cardiac cells would have a broad impact on all
steps of this process. In particular, phosphatase inhibitors might
mimic the action of signaling cascades that activate PKC or PKA.
-Adrenergic stimulation, acting through PKC, increases myofilament
Ca2+ sensitivity (21), decreases time- and
voltage-dependent K+ currents (1, 18), and
produces a contractile effect similar to that seen here for calyculin A
(18).
-Adrenergic stimulation, acting through PKA,
produces positive inotropic and lusitropic effects by increasing the
magnitude of the Ca2+ current (8, 24),
increasing SR Ca2+ uptake (31, 33), and
decreasing myofilament Ca2+ sensitivity (21).
Unexpectedly, however, the results here reveal that when the major
phosphatases in the heart are broadly inhibited by calyculin A, the
acute contractile effects cannot be explained by a global effect on the
entire E-C coupling cascade. Rather, these new findings raise several
questions central to the local steady-state control of E-C coupling by
phosphatases in the heart.
Phosphatase inhibition and myofilament Ca2+ sensitivity. To examine potential increases in myofilament Ca2+ sensitivity, we utilized an unloaded permeabilized cell model. This method was very effective in measuring steady-state myofilament Ca2+ sensitivity over a concentration range in which such increases would be evident. Control experiments with caffeine validated this approach. Because no increases in myofilament Ca2+ sensitivity were observed with calyculin A at Ca2+ concentrations as high as 500 nM, it cannot account for the inhibitor-evoked increase in the magnitude and duration of contraction. A limitation of this unloaded cell approach is that cell shortening could not be assessed over the complete physiologically relevant Ca2+ concentration range. Thus it is not possible to exclude the possibility that phosphatase inhibition with calyculin A actually decreased myofilament Ca2+ sensitivity. It is also possible that phosphorylation-dependent changes in dynamic myofilament properties, such as the cross-bridge cycling rate (48), could occur that would not be detected in these steady-state measurements. However, taken together, these studies reveal that PP1/PP2A inhibition does not prolong the twitch duration through an increase in the steady-state Ca2+-dependent properties of the myofilaments.
Phosphatase inhibition and repolarizing
K+ currents.
The similarity between the effects of calyculin A and
-adrenergic
agonists on contractility and action potential duration (18) suggested that the time- and voltage-dependent
repolarizing K+ currents are regulated by PP1/PP2A
inhibition. In fact, phosphatase inhibitors have been shown to decrease
delayed rectifier K+ currents in the frog atrium
(20). Furthermore,
1-adrenergic agonists
increase the magnitude and duration of contractions (18), prolong action potentials (1, 18), and reduce
K+ currents in isolated rat ventricular myocytes (1,
18) through activation of PKC (1). The mouse
ventricle exhibits a wide variety of time- and voltage-dependent
K+ currents. There are two transient outward currents,
termed Ito,f and Ito,s
for their fast and slow inactivation kinetics, respectively (51). In addition, there is a rapidly activating, slowly
inactivating current, termed IK,slow (14,
19, 51, 53), and a noninactivating current, termed
IK,ss (14, 51). In addition, the
mouse also possesses IK1, which is responsible
for maintaining the resting potential but has also been shown to affect
action potential duration (52). Precise pharmacological
separation of these currents is difficult because there are no specific
blockers that allow observation of each component in isolation. Kinetic
separation of these currents requires the use of very long
voltage-clamp pulses. In a recent study (14), we
demonstrated that agents that affect any individual K+
current will also affect the composite K+ current, which
can be separated into a transient and a maintained component. In the
present study, we report that calyculin A was completely without effect
on either the transient or maintained component of the current (Fig.
5D). Furthermore, there was no effect on the recovery from
inactivation of either component over the range of 20 ms to nearly
3 s. Thus inhibition of PP1/PP2A has no effect on these
K+ currents and cannot explain the increase in
contractility that we observe (Fig. 3). It is interesting to note that
calcineurin, the calcium/calmodulin-dependent phosphatase, does not
regulate cardiac K+ currents either (12, 14).
Thus ventricular K+ currents, in contrast to
ICa, are not locally regulated by any of the
major serine-threonine phosphatases.
Phosphatase inhibition and ICa.
Of the targets studied in this report, the L-type Ca2+
channel proved to be the most sensitive to PP1/PP2A inhibition. This might have been expected because phosphatase inhibitors increase ICa in both frog atrial and guinea pig
ventricular myocytes (20, 23, 27, 28, 40, 41).
Furthermore, okadaic acid increases ICa in
isolated single channels (43, 50), underscoring the role
of local PP1 and perhaps PP2A in dynamic control of L-type Ca2+ channel activity. In this regard, a recent biochemical
study (10) demonstrated that PP2A binds directly to the
-subunit of the cardiac L-type Ca2+ channel. Taken
together, these data demonstrate that in intact cells the L-type
Ca2+ channel is very sensitive to serine-threonine
phosphatase activity in the absence of humoral stimulation. It is also
clear that the L-type Ca2+ channel is equally sensitive to
serine-threonine kinase activity, as demonstrated by the fact that the
broad-spectrum kinase inhibitor staurosporine decreased
ICa and prevented the stimulatory action of
calyculin A. It will be important to identify the underlying kinases
that oppose the phosphatase action and regulate
ICa under these conditions.
Phosphatase inhibition and SR Ca2+
uptake.
During the course of these studies, analysis of the action of calyculin
A revealed conflicting results regarding SR Ca2+ uptake. In
particular, phosphatase inhibition accelerated the decay of the
voltage-clamp-induced [Ca2+]i transient,
whereas it markedly prolonged the duration of the field-stimulated
twitch contraction. This apparent discrepancy raised uncertainty about
the role of serine-threonine phosphatases in regulating SR
Ca2+ pump activity in the absence of humoral stimulation.
It is important to note that the
of
[Ca2+]i decay decreases as the magnitude of
the [Ca2+]i transient increases
(5). Because calyculin A markedly increases peak
[Ca2+]i, the concomitant increase in the
decay rate of the [Ca+]i transient does not
prove that SR Ca2+ uptake is activated.
-adrenergic agonist isoproterenol on
[Ca2+]i transients and contractions in
field-stimulated cells.
-Adrenergic stimulation is known to greatly
stimulate the activity of the SR Ca2+ pump (34,
47). Several lines of experimental evidence indicated that
phosphatase inhibition alone did not substantially increase SR
Ca2+ pump activity. First, calyculin A did not change the
T50 of the [Ca2+]i
transient, whereas isoproterenol decreased it by 25% (Fig. 8 and Table
1). Second, isoproterenol had a much greater effect on the
of
[Ca2+]i decay than did calyculin A
(Table 1). Because peak [Ca2+]i was the same
with both calyculin A and isoproterenol (Table 1), this difference
reflects a real difference in the rates of SR Ca2+ pump
activity (5). These functional results are consistent with
the recent biochemical observation that cantharidin, another PP1/PP2A
inhibitor, does not increase the phosphorylation state of the PKA site,
Ser16, on phospholamban in the guinea pig ventricle
(7). We conclude from our measurements of
[Ca2+]i decay that calyculin A produces no
stimulation of the mouse ventricular SR Ca2+-ATPase. Thus
the prolongation of contraction results from the fact that
[Ca2+]i remains in the range that fully
activates myofilaments for a longer period of time and, even though the
T50 of the [Ca2+]i
transient is the same as that of the control, the
[Ca2+]i at T50 is
substantially higher.
In summary, the use of a rapid and potent PP1/PP2A inhibitor has
provided insight into the range of action of this important family of
phosphatases in controlling the E-C coupling cascade in cardiac
myocytes in the absence of neural or humoral stimulation. Precise
functional analyses here reveal that, rather than controlling many
steps in the cascade, these signaling enzymes have a major role
principally in the regulation of steady-state L-type Ca2+
channel activity. It will be important to know if such a dynamic balance of phosphorylation is altered under conditions of heart failure.
| |
ACKNOWLEDGEMENTS |
|---|
This work was supported in part by National Institutes of Health Grants PO1 HL-27867, AG-1463 (to T. B. Rogers), and HL-36874 (to W. J. Lederer), and in part by a GIA grant from the American Heart Association, Maryland Affiliate (to X. Long).
| |
FOOTNOTES |
|---|
* W. H. duBell and M. S. Gigena contributed equally to the data presented in this work.
Address for reprint requests and other correspondence: T. B. Rogers, Dept. of Biochemistry and Molecular Biology, Univ. of Maryland, 108 N. Greene St., Baltimore, MD 21201 (E-mail: trogers{at}som.umaryland.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
First published September 27, 2001; 10.1152/ajpheart.00536.2001
Received 25 June 2001; accepted in final form 20 September 2001.
| |
REFERENCES |
|---|
|
|
|---|
1.
Apkon, M,
and
Nerbonne JM.
1-Adrenergic agonists selectively suppress voltage-dependent K+ currents in rat ventricular myocytes.
Proc Natl Acad Sci USA
85:
8756-8760,
1988.
2.
Armstrong, SC,
Gao W,
Lane JR,
and
Ganote CE.
Protein phosphatase inhibitors calyculin A and fostriecin protect rabbit cardiomyocytes in late ischemia.
J Mol Cell Cardiol
30:
61-73,
1998.
3.
Armstrong, SC,
Hoover DB,
Delacey MH,
and
Ganote CE.
Translocation of PKC, protein phosphatase inhibition and preconditioning of rabbit cardiomyocytes.
J Mol Cell Cardiol
28:
1479-1492,
1996.
4.
Berrebi-Bertrand, I,
Brument-Larignon N,
Camelin JC,
Quiniou MJ,
and
Bril A.
Relationship between biochemical and functional effects of protein phosphatase 1 inhibitors in rabbit cardiac skinned fibers.
J Mol Cell Cardiol
30:
1945-1954,
1998.
5.
Bers, DM,
and
Berlin JR.
Kinetics of [Ca]i decline in cardiac myocytes depend on peak [Ca]i.
Am J Physiol Cell Physiol
268:
C271-C277,
1995.
6.
Bialojan, C,
and
Takai A.
Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics.
Biochem J
256:
283-290,
1998.
7.
Boknik, P,
Khorchidi S,
Bodor GS,
Huke S,
Knapp J,
Linck B,
Luss H,
Muller FU,
Schmitz W,
and
Neumann J.
Role of protein phosphatases in regulation of cardiac inotropy and relaxation.
Am J Physiol Heart Circ Physiol
280:
H786-H794,
2001.
8.
Brum, G,
Osterrieder W,
and
Trautwein W.
-Adrenergic increase in the calcium conductance of cardiac myocytes studied with the patch clamp.
Pflügers Arch
401:
111-118,
1984.
9.
Cohen, P,
Alemany S,
Hemmings BA,
Resink TJ,
Stralfors P,
and
Lim Tung HY.
Protein phosphatase-1 and protein phosphatase-2A from rabbit skeletal muscle.
Methods Enzymol
159:
390-408,
1988.
10.
Davare, MA,
Horne MC,
and
Hell JW.
Protein phosphatase 2A is associated with class C L-type calcium channels (Cav1.2) and antagonizes channel phosphorylation by cAMP-dependent protein kinase.
J Biol Chem
275:
39710-39717,
2000.
11.
Dell'Acqua, ML,
and
Scott JD.
Protein kinase A anchoring.
J Biol Chem
272:
12881-12884,
1997.
12.
DuBell, WH,
Gaa ST,
Lederer WJ,
and
Rogers TB.
Independent inhibition of calcineurin and K+ currents by the immunosuppressant FK-506 in rat ventricle.
Am J Physiol Heart Circ Physiol
275:
H2041-H2052,
1998.
13.
DuBell, WH,
Lederer WJ,
and
Rogers TB.
Dynamic modulation of excitation-contraction coupling by protein phosphatases in rat ventricular myocytes.
J Physiol (Lond)
493:
793-800,
1996.
14.
DuBell, WH,
Lederer WJ,
and
Rogers TB.
K+ currents responsible for repolarization in mouse ventricle and their modulation by FK-506 and rapamycin.
Am J Physiol Heart Circ Physiol
278:
H886-H897,
2000.
15.
Eisner, DA,
and
Valdeolmillos M.
The mechanism of the increase of tonic tension produced by caffeine in sheep cardiac Purkinje fibres.
J Physiol (Lond)
364:
313-326,
1985.
16.
Fabiato, A,
and
Fabiato F.
Calculator programs for computing the composition of the solutions containing multiple metals and ligands used for experiments in skinned muscle cells.
J Physiol (Paris)
75:
463-505,
1979.
17.
Favre, B,
Turowski P,
and
Hemmings BA.
Differential inhibition and posttranslational modification of protein phosphatase 1 and 2A in MCF7 cells treated with calyculin-A, okadaic acid and tautomycin.
J Biol Chem
272:
13856-13863,
1997.
18.
Fedida, D,
and
Bouchard RA.
Mechanism for the positive inotropic effect of
1-adrenoceptor stimulation in rat cardiac myocytes.
Circ Res
71:
673-688,
1992.
19.
Fiset, C,
Clark RB,
Larsen TS,
and
Giles WR.
A rapidly activating sustained K+ current modulates repolarization and excitation-contraction coupling in adult mouse ventricle.
J Physiol (Lond)
505:
557-563,
1997.
20.
Frace, AM,
and
Hartzell HC.
Opposite effects of phosphatase inhibitors on L-type calcium and delayed rectifier currents in frog cardiac myocytes.
J Physiol (Lond)
472:
305-326,
1993.
21.
Gambassi, G,
Spurgeon HA,
Lakatta EG,
Blank PS,
and
Capogrossi MC.
Different effects of
and
-adrenergic stimulation on cytosolic pH and myofilament responsivness to Ca2+ in cardiac myocytes.
Circ Res
71:
870-882,
1992.
22.
Gao, T,
Yatani A,
Dell'Acqua ML,
Sako H,
Green SA,
Dascal N,
Scott JD,
and
Hosey MM.
cAMP-dependent regulation of cardiac L-type Ca2+ channels requires membrane targeting of PKA and phosphorylation of channel subunits.
Neuron
19:
185-196,
1997.
23.
Hartzell, HC,
Hirayama Y,
and
Petit-Jacques J.
Effects of protein phosphatase and kinase inhibitors on the cardiac L-type Ca current suggest two sites are phosphorylated by protein kinase A and another protein kinase.
J Gen Physiol
106:
393-414,
1995.
24.
Haworth, RA,
Griffin P,
Saleh B,
Goknur AB,
and
Berkoff HA.
Contractile function of isolated young and adult rat heart cells.
Am J Physiol Heart Circ Physiol
253:
H1484-H1491,
1987.
25.
Herzig, JE,
Köhler G,
Pfitzer G,
Rüegg JC,
and
Wölffle G.
Cyclic AMP inhibits contractility of detergent treated glycerol-extracted cardiac muscle.
Pflügers Arch
391:
208-212,
1981.
26.
Hescheler, J,
Kameyama M,
Trautwein W,
Mieskes G,
and
Soling HD.
Regulation of the cardiac calcium channel by protein phosphatases.
Eur J Biochem
165:
261-266,
1987.
27.
Hescheler, J,
Mieskes G,
Ruegg JC,
Takai A,
and
Trautwein W.
Effects of a protein phosphatase inhibitor, okadaic acid, on membrane currents of isolated guinea-pig cardiac myocytes.
Pflügers Arch
412:
248-252,
1988.
28.
Hirayama, Y,
and
Hartzell HC.
Effects of protein phosphatase and kinase inhibitors on Ca2+ and Cl
currents in guinea pig ventricular myocytes.
Mol Pharmacol
52:
725-734,
1997.
29.
Huang, X,
Pi Y,
Lee KJ,
Henkel AS,
Gregg RG,
Powers PA,
and
Walker JW.
Cardiac troponin I gene knockout: a mouse model of myocardial troponin I deficiency.
Circ Res
84:
1-8,
1999.
30.
Ishihara, H,
Martin BL,
Brautigan DL,
Karaki H,
Ozaki H,
Kato Y,
Fusetani N,
Watabe S,
Hashimoto K,
and
Uemura D.
Calyculin A and okadaic acid: inhibitors of protein phosphatase activity.
Biochem Biophys Res Commun
159:
871-877,
1989.
31.
James, P,
Inui M,
Tada M,
Chiesi M,
and
Carafoli E.
Nature and site of phospholamban regulation of the Ca2+ pump of sarcoplasmic reticulum.
Nature
342:
90-92,
1989.
32.
Kuschel, M,
Zhou YY,
Cheng H,
Zhang SJ,
Chen Y,
Lakatta EG,
and
Xiao RP.
Gi protein-mediated functional compartmentalization of cardiac
2-adrenergic signaling.
J Biol Chem
274:
22048-22052,
1999.
33.
Lindemann, JP,
Jones LR,
Hathaway DR,
Henry BG,
and
Watanabe AM.
-Adrenergic stimulation of phospholamban phosphorylation and Ca2+-ATPase activity in guinea pig ventricles.
J Biol Chem
258:
464-471,
1983.
34.
MacDougall, LK,
Jones LR,
and
Cohen P.
Identification of the major protein phosphatases in mammalian cardiac muscle which dephosphorylate phospholamban.
Eur J Biochem
196:
725-734,
1991.
35.
Marks, AR.
Cardiac intracellular calcium release channels.
Circ Res
87:
8-11,
2000.
36.
Marx, SO,
Reiken S,
Hisamatsu Y,
Jayaraman T,
Burkhoff D,
Rosemblit N,
and
Marks AR.
PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts.
Cell
101:
365-376,
2000.
37.
Mochly-Rosen, D,
Wu G,
Hahn H,
Osinska H,
Liron T,
Lorenz JN,
Yatani A,
Robbins J,
and
Dorn GW II.
Cardiotrophic effects of protein kinase C
: analysis by in vivo modulation of PKC
translocation.
Circ Res
86:
1173-1179,
2000.
38.
Mumby, MC,
Russell KL,
Garrad LJ,
and
Green DD.
Cardiac contractile protein phosphatases: purification of two enzyme forms and their characterization with subunit-specific antibodies.
J Biol Chem
262:
6257-6265,
1987.
39.
Narayan, P,
Mentzer RM,
and
Lasley RD.
Phosphatase inhibitor cantharidin blockes adenosine A1 receptor antiadrenergic effect in rat cardiac myocytes.
Am J Physiol Heart Circ Physiol
278:
H1-H7,
2000.
40.
Neumann, J,
Boknik P,
Herzig S,
Schmitz W,
Scholz H,
Gupta RC,
and
Watanabe AM.
Evidence for physiological functions of protein phosphatases in the heart: evaluation with okadaic acid.
Am J Physiol Heart Circ Physiol
265:
H257-H266,
1993.
41.
Neumann, J,
Boknik P,
Herzig S,
Schmitz W,
Scholz H,
Wiechen K,
and
Zimmerman N.
Biochemical and electrophysiological mechanisms of the positive inotropic effect of calyculin A, a protein phosphatase inhibitor.
J Pharmacol Exp Ther
271:
535-541,
1994.
42.
Okazaki, O,
Suda N,
Hongo K,
Konishi M,
and
Kurihara S.
Modulation of Ca2+ transients and contractile properties by
-adrenoceptor stimulation in ferret ventricular myocytes.
J Physiol (Lond)
423:
221-240,
1990.
43.
Ono, K,
and
Fozzard HA.
Two phosphatase sites on the Ca2+ channel affecting different kinetic functions.
J Physiol (Lond)
470:
73-84,
1993.
44.
Pinna, LA,
and
Donella-Deana A.
Phosphorylated synthetic peptides as tools for studying protein phosphatases.
Biochim Biophys Acta
1222:
415-431,
1994.
45.
Rodriguez, MM,
Ron D,
Ron D,
Chen CH,
and
Mochly-Rosen D.
RACK1, a protein kinase C anchoring protein, coordinates the binding of activated protein kinase C and select pleckstrin homology domains in vitro.
Biochemistry
38:
13787-13794,
1999.
46.
Ruegg, UT,
and
Burgess GM.
Staurosporin, K-252, and UCN-01: potent but nonspecific inhibitors of protein kinases.
Trends Pharmacol Sci
10:
18-22,
1989.
47.
Steenaart, NAE,
Ganim JR,
DiSalvo J,
and
Kranias EG.
The phospholamban phosphatase associated with cardiac sarcoplasmic reticulum is a type 1 enzyme.
Arch Biochem Biophys
293:
17-24,
1992.
48.
Weisberg, A,
and
Weiser R.
Alteration of myosin cross bridges by phosphorylation of myosin-binding protein C in cardiac muscle.
Proc Natl Acad Sci USA
93:
8999-9003,
1996.
49.
Wendt, IR,
and
Stephensen DG.
Effects of caffeine on Ca-activated force production in skinned cardiac and skeletal muscle fibres of the rat.
Pflügers Arch
398:
210-216,
1983.
50.
Wiechen, K,
Yue DT,
and
Herzig S.
Two distinct functional effects of protein phosphatase inhibitors on guinea-pig cardiac L-type Ca2+ channels.
J Physiol (Lond)
484:
583-592,
1995.
51.
Xu, H,
Guo W,
and
Nerbonne JM.
Four kinetically distinct depolarization-activated K+ currents in adult mouse ventricular myocytes.
J Gen Physiol
113:
661-677,
1999.
52.
Zaritsky, JJ,
Redell JB,
Tempel BL,
and
Schwarz TL.
The consequences of disrupting cardiac inwardly rectifying K+ current (IK1) as revealed by the targeted deletion of the murine Kir2.1 and Kir2.2 genes.
J Physiol (Lond)
533:
697-710,
2001.
53.
Zhou, J,
Jeron A,
London B,
Han X,
and
Koren G.
Characterization of a slowly inactivating outward current in adult mouse ventricular myocytes.
Circ Res
83:
806-814,
1998.
This article has been cited by other articles:
![]() |
H. Tsujikawa, Y. Song, M. Watanabe, H. Masumiya, S. A. Gupte, R. Ochi, and T. Okada Cholesterol depletion modulates basal L-type Ca2+ current and abolishes its -adrenergic enhancement in ventricular myocytes Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H285 - H292. [Abstract] |